Riskpilot← Back to searchSign inGet full accessIbraheem Consult AB
ABActiveOrg 5590834734Badstrandsvägen 2 BMedical specialists activities · NACE 8622Est. 20160 employees
Revenue 2024
SEK 1,6M
+197% vs 2023
EBITDA margin
11.5%
+64% vs 2023
Equity ratio
35.5%
Financial strength
Net profit 2024
SEK 194K
+385% vs 2023
| Revenue | SEK 1,6M | +197% |
| EBITDA | SEK 183K | +64% |
| Net profit | SEK 194K | +385% |
| Total assets | SEK 693K | +82% |
| Equity | SEK 246K | +111% |
| Employees | 0 | — |
Legal name
Ibraheem Consult AB
Org number
5590834734
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
3 november 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av suppleanten
Company purpose
Specialist inom ögonsjukdomar.
Address
Badstrandsvägen 2 B
Email
yasseenthamir@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 476 | 581 | 743 | 538 | 1 599 |
| Staff expenses | — | — | −201 | −136 | −1 030 |
| EBITDA | 93 | 236 | 203 | 112 | 183 |
| Depreciation & amort. | −38 | −44 | −45 | −51 | −49 |
| EBIT | 55 | 192 | 157 | 61 | 134 |
| Net financials | — | — | −0 | −1 | −2 |
| Profit before tax | 55 | 136 | 112 | 60 | 250 |
| Tax | −12 | −38 | −28 | −20 | −56 |
| Net profit | 43 | 98 | 84 | 40 | 194 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 403 | 383 | 470 | 382 | 693 |
| Equity | 169 | 157 | 152 | 117 | 246 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 171 | 108 | 155 | 102 | 402 |
| Total debt | 171 | 108 | 155 | 102 | 402 |
EBITDA margin
11.5%
This company
15.8%
Market median
-27% vs market
20202024
Equity ratio
35.5%
This company
38.2%
Market median
+7% vs market
20202024
Return on equity
79.0%
This company
18.4%
Market median
+329% vs market
20202024
Net profit margin
12.2%
This company
8.1%
Market median
+51% vs market
20202024
Asset turnover
2.31×
This company
1.12×
Market median
+106% vs market
20202024
Debt / equity
1.82×
This company
0.62×
Market median
-194% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ibraheem Consult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Yasseen Munthir Thamir | Board of Directors | 0 companies |
| Munthir Thamir Ibraheem | Board of Directors | 0 companies |
| Samar Samir Mohammed Khadar | Deputy Board Member | 0 companies |